Article Per Year (5 Year)
p-Index From 2019 - 2024
0
P-Index
This Author published in this journals
All Journal Paediatrica Indonesiana
Bidasari Lubis
Department of Child Health, University of Sumatera Utara Medical School/H. Adam Malik Hospital, Medan, North Sumatera
Health Professions Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Quality of life assessment of children with thalassemia Masyitah Sri Wahyuni; Muhammad Ali; Nelly Rosdiana; Bidasari Lubis
Paediatrica Indonesiana Vol 51 No 3 (2011): May 2011
Publisher : Indonesian Pediatric Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (150.968 KB) | DOI: 10.14238/pi51.3.2011.163-9

Abstract

Background Thalassemia is a chronic disease that is becoming a major health problem in the world, including the Mediterranean, as well as Malaysia, Thailand and Indonesia. This condition clearly affects the patient's quality of life, because of the condition itself andthe effects of treatment. Assessment is needed to detennine actions to be taken to improve the quality of life in thalassemic children.Objective To assess the differences in quality of life of thalassemic children compared to their normal siblings.Methods We perfonned a cross􀁌sectional study from May 2010 until June 2010 in H. Adam Malik Hospital, Medan and the home of a member of the North Sumatra Chapter of the Association of Parents of Thalassemia Sufferers (perhimpunan Orangtua PenderitaTalasemia Indonesia, POPTI). Thalassemic children aged 5-18 years and their age and gender􀁌adjusted siblings were divided into two groups: case group and control group. Parents and children were asked to fill the PedsQL (Pediatric Quality of life Inventory)version 4.0 questionnaire to assess their quality of life.Results There were 59 children in each group. The assessments of four quality of life domains in the thalassemic group vs the control group showed the folloMng: physical function 53.1 vs 71.5 (95% CI -21.41 to -15.26, P􀁍O.OOOI), emotional function 50.9 vs 62.9 (95% CI -16.82 to -7 .41, P􀁍O.OOO 1), social function 62.5 vs 72.8 (95% CI-13.50 to -7.01, P􀁍O.OOOI) and school function 36.2 vs 56.0 (95% CI -22.95 to -16.71, P􀁍O.OOOI). Total scores were 50.9 vs 66.1 (95% CI -18.20to -13.12, P􀁍O.OOOI). School function was the most affected parameter studied, with thalassemic children scoring lower than the control group.Conclusion There were significant decreases in the quality of life parameters in the thalassemic group compared to the control group. Thalassemic children have poorer quality oflife compared to their nonnal siblings, Mth school function being the mostaffected domain. 
Relationship between the general condition of acute lymphoblastic leukemia patients with remission rate and convulsion as an adverse effect chemotherapy Rusdi Andid; Nurdiani Nurdiani; Bidasari Lubis; Adi Sutjipto
Paediatrica Indonesiana Vol 41 No 1-2 (2001): January 2001
Publisher : Indonesian Pediatric Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (367.223 KB) | DOI: 10.14238/pi41.1.2001.33-7

Abstract

A retrospective study on the relationship between the general condition of acute lymphoblastic leukemia patients with remission rale and convulsion as an adverse effect of chemotherapy was conducted in leukemia patients of the hematology-oncology subdivision, Departmenl of Child Health, Medical School, University of North Sumatra, Medan. Of 114 children with acute lymphoblastic leukemia, 81 (71.05%) received chemotherapy, 31 patients among them was in good general condition. Remission rate of the 31 patients was 80.6% (25 children). Whereas in the remaining 50 patients, the remission rate among them was 84% (42 patients). There was no significant relationship between their general condition to the recurrence rate of acute lymphoblastic leukemia patients who had been administered chemotherapy during induction phase. Convulsion was found In 2 cases, due to CNS leukemia.
The addition of omeprazole to ondansetron for treating chemotherapy-induced nausea and vomiting in pediatric cancer patients Perjuangan Dapot Hamonangan Simbolon; Selvi Nafianti; Pertin Sianturi; Bidasari Lubis; Aznan Lelo
Paediatrica Indonesiana Vol 58 No 1 (2018): January 2018
Publisher : Indonesian Pediatric Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (81.546 KB) | DOI: 10.14238/pi58.1.2018.42-7

Abstract

Background Chemotherapy-induced nausea and vomiting are some of the most disturbing side effects in pediatric cancer patients. The standard recommendation is the use of 5-hydroxytryptamine 3 receptor antagonist, such as ondansetron, to treat these symptoms. Despite this treatment, more than 50% of patients still experience nausea and vomiting. Objective To evaluate the effect of the addition of omeprazole to ondansetron in the treatment of chemotherapy-induced nausea and vomiting. Methods A double-blind, randomized, controlled trial was conducted at Haji Adam Malik Hospital, Medan, North Sumatera, from March to May 2016. Subjects were children aged 1 to 18 years, diagnosed with cancer, and who received intravenous chemotherapy. Patients were randomized to receive either a single dose of ondansetron (0.5 mg/kg) plus placebo or ondansetron (0.5 mg/kg) plus omeprazole (0.5 mg/kg). The severity of nausea and vomiting were measured using the Rhodes index of nausea, vomiting, and retching during the 24 hours after initiation of emetogenic chemotherapy. The primary outcome of efficacy was the proportion of patients who achieved complete response (lack of nausea/vomiting). Statistical analysis was performed by Chi-square and Fischer’s exact tests. Results Seventy eligible pediatric patients were randomized into two groups: 32 subjects in the ondansetron + placebo group and 38 others in the ondansetron + omeprazole group. The therapy failed in 50% (16/32) of the ondansetron + placebo group and 18.4% (7/38) of the ondansetron + omeprazole group. There was a significant difference in the clinical response between groups (P=0.01). Conclusion The addition of omeprazole to ondansetron for the treatment of chemotherapy-induced nausea and vomiting is more effective than administration of ondansetron alone.
Co-Authors Adi Sutjipto Aznan Lelo Masyitah Sri Wahyuni Muhammad Ali Nelly Rosdiana Nurdiani Nurdiani Perjuangan Dapot Hamonangan Simbolon Pertin Sianturi Rusdi Andid Selvi Nafianti